|
|
 |
|
Viewing report
|
|
|
|
Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost
GBI Research, May 2011, Pages: 93
Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost
Summary
GBI Research has released its research, “Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost”, which provides insights into recruitment strategies, challenges and solutions for on-time recruitment in oncology trials. The report also examines case studies to illustrate enhanced recruitment in a shorter time. The A provides an in-depth analysis of the trials conducted by major pharmaceutical companies for the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and brain cancer.
GBI Research analyzed the critical factors that are responsible for the increase in timelines of the completion of clinical trials, the increase in costs to conduct a clinical trial, and the delay in time to market. Adaptive clinical trials are aimed at striking a balance between the needed dose response information and the increased cost associated with it. The simulation of clinical trials allows pharmaceutical companies to compare and contrast the operating characteristics of the design options. Modeling, forecasting and tracking the clinical trial enrollment gives an opportunity for the team to identify the problems before they happen. This results in lowering the clinical trial cost and speeds up the time to regulatory submission. Companies wanting to reduce potential discrepancies in the process and save costs are utilizing these solutions.
Oncology clinical trials are complex and involve a more diverse approach than trials in many other therapeutic areas. The most challenging obstacle, especially in the US, is patient recruitment, where oncology trials have notoriously low participation rates among adult patients. While more than 1.2 million Americans were newly diagnosed with cancer in 2010, participation in oncology trials remains very low. According to the American Society of Clinical Oncology (ASCO), only 3% of US adults with cancer participated in clinical trials. Lack of participation can cause an oncology trial to recruit slowly, often lengthening the trial’s timeline by months or even years.
Scope
The scope of this report includes -
- Status of oncology trials share by geography, therapeutic area and major pharmaceutical companies.
- Cost of patient recruitment in oncology as a share of clinical trial.
- Site selection in oncology trials in multiple site trials, based on infrastructure, incidence, and study staff availability.
- Key drivers and restraints that have had a significant impact on the patient recruitment.
- Outsourcing patient recruitment to Clinical Research Organizations (CROs) to reduce the recruitment time.
- Use of IT-enabled patient recruitment systems making use of Electronic Health Records of patients, which reduces recruitment cost and time and provides better patient availability.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Build effective strategies for recruitment of patients in trials by reducing the drug’s time to market.
- Exploit strategies for retention of patients by identifying the barriers and challenges involved.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop a better study design for better patient recruitment.
- Build a protocol involving less budget and more patients in less time.
|
|
|
|
